Immutep Ltd has released a press release.
Immutep presents positive TACTI-mel melanoma trial data
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Immutep receives A$2.5M R&D French Tax Incentive
- Immutep expands Part A of TACTI-002 due to positive data
- Immutep to receive GBP4M Milestone Payment from GSK
- Japanese patent granted for LAG525 antibody
- Immutep granted European patent for IMP321 in cancer
Later from Immutep
- Appendix 4C - quarterly
- Immutep announces European patent grant for LAG525 antibody
- INSIGHT-004 clinical trial update
- Immutep expands Part C of TACTI-002 due to positive data
- Immutep Activities Report
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep